BACKGROUNDThe relationship between malignancy and thrombosis is known for over 100 years. Thrombocytosis, an increase in fibrinogen and fibrin degradation products like D-dimer arise in factors V, VII, VIII, IX and XI levels and a decrease in antithrombin III are seen in cancer patients. Extracellular remodeling of fibrin is essential for angiogenesis in tumours and activation of intravascular fibrin formation and degradation has been shown to occur in the plasma of breast cancer patients. The objectives of this study are-1. To correlate plasma level of coagulation markers (D-dimer) with clinico-pathological stage of carcinoma breast. 2. To assess role of coagulation markers (D-dimer) value as predictive markers of lymph node metastasis in breast cancer. 3. To assess changes in D-dimer values according to increasing (pathological) lymph node involvement. MATERIALS AND METHODSThis study was conducted in the Department of Surgery in Dr. S. N. Medical College, Jodhpur, Rajasthan, India and included 25 patients admitted in surgery ward from January 2016 to June 2017 (Prospective study). HPE of breast specimen was done and pathological examination report were analysed with Plasma D-Dimer value. RESULTSThere was statistically significant correlation between mean values of plasma D-Dimer and advancing stage of disease, tumour size, histological grade and lymphovascular invasion. BACKGROUND Breast cancer is the most common cancer in women and accounts for 29% of all cancers diagnosed each year in women all over the world. 1 Considering the magnitude of problem, it becomes of paramount importance to take various patients and tumour characteristics into consideration while chalking out the treatment plan for the patient. Lymph node metastasis has been shown to be the most important prognostic marker for carcinoma breast. 2,3 Lymph node involvement is not only a prognosis marker, but also an important guiding factor in deciding surgical plan as well as postoperative therapy. Presently, sentinel lymph node biopsy is considered gold standard to assess lymph node metastasis in carcinoma breast with clinically negative axilla. 4 'Financial or Other Competing Interest': None. Submission 04-10-2017, Peer Review 10-11-2017, Acceptance 18-11-2017, Published 27-11-2017. Corresponding Author: Dr. Man Singh Bairwa, Room No. 18, First Floor, P. G. Hostel, MGH Campus, Jodhpur-342001, Rajasthan. E-mail: drmansinghb@gmail.com DOI: 10.14260/jemds/2017/1402 Search for a marker, which can predict lymph node metastasis in clinically negative axilla has been a matter of research for long. 5 There is ample evidence that the components of the coagulation/ fibrinolytic system play an important role in cancer biology and angiogenesis. Fibrin deposition and remodeling in extracellular matrix of the tumour is an important initial step in tumour metastasis. For a tumour to successfully metastasise from its primary location, it must undergo several obligate steps including the invasion into either the lymphatic or vascular lumen, tr...
Background: World-wide breast cancer is the most frequent type of cancer among females with increasing incidence. Methods: This study was retrospective and prospective both. Total 40 Female patients of Breast cancer, from all age group admitted in Department of Surgery, Dr. S.N. Medical College, Jodhpur were included. Results: Lump was presenting feature in all cases 100%. The next most common presenting feature was pain, which was present in 62.5% cases. 10%, 17.5% and 2.5% cases had nipple discharge, nipple retraction and skin ulceration. Conclusion: The highest incidence of breast carcinoma was in 4th, 5th and 6the decades.Majority of the patients was Hindus and of rural areas and all the patients were married female. Keywords: Breast Carcinoma, Histopathologically Positive, Metastasis
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.